PAI-1, il principale inibitore plasmatico della fibrinolisi. Ruolo fisiopatologico e meccanismi molecolari.

Translated title of the contribution: PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms

C. Banfi, L. Mussoni, E. Tremoli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in blood. PAI-1 is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular diseases. Plasma levels of PAI-1 are regulated on a genetic basis but, more important, is the dependence on a series of other atherosclerotic risk factors like hypertriglyceridemia, diabetes and insulin resistance. The insulin resistance syndrome, which is characterized partly by obesity with visceral fat accumulation, is considered as a major regulator of PAI-1 expression. At least in vitro, insulin is a potent inducer of PAI-1 synthesis by human hepatic cells, and, we have recently disentangled the molecular mechanisms responsible for enhanced PAI-1 gene expression by insulin. However, clinical data fail to support a direct acute contribution of insulin in regulating circulating PAI-1 levels. Recently, it has been proposed that adipose tissue could be responsible for the elevated plasma PAI-1 level observed in insulin resistance. It now seems reasonable to view PAI-1 as one of the factors contributing to the complex gene-environment interactions involved in the formation and dissolution of thrombi.

Original languageItalian
Pages (from-to)181-191
Number of pages11
JournalMinerva Endocrinologica
Volume27
Issue number3
Publication statusPublished - 2002

Fingerprint

Plasminogen Activator Inhibitor 1
Fibrinolysis
Insulin Resistance
Insulin
Thrombosis
Gene-Environment Interaction
Intra-Abdominal Fat
Hypertriglyceridemia
Plasminogen
Adipose Tissue
Hepatocytes
Chronic Disease
Cardiovascular Diseases
Obesity
Gene Expression

Cite this

PAI-1, il principale inibitore plasmatico della fibrinolisi. Ruolo fisiopatologico e meccanismi molecolari. / Banfi, C.; Mussoni, L.; Tremoli, E.

In: Minerva Endocrinologica, Vol. 27, No. 3, 2002, p. 181-191.

Research output: Contribution to journalArticle

@article{10f13c4e24584aadbd2c09ed02b7dbc8,
title = "PAI-1, il principale inibitore plasmatico della fibrinolisi. Ruolo fisiopatologico e meccanismi molecolari.",
abstract = "Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in blood. PAI-1 is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular diseases. Plasma levels of PAI-1 are regulated on a genetic basis but, more important, is the dependence on a series of other atherosclerotic risk factors like hypertriglyceridemia, diabetes and insulin resistance. The insulin resistance syndrome, which is characterized partly by obesity with visceral fat accumulation, is considered as a major regulator of PAI-1 expression. At least in vitro, insulin is a potent inducer of PAI-1 synthesis by human hepatic cells, and, we have recently disentangled the molecular mechanisms responsible for enhanced PAI-1 gene expression by insulin. However, clinical data fail to support a direct acute contribution of insulin in regulating circulating PAI-1 levels. Recently, it has been proposed that adipose tissue could be responsible for the elevated plasma PAI-1 level observed in insulin resistance. It now seems reasonable to view PAI-1 as one of the factors contributing to the complex gene-environment interactions involved in the formation and dissolution of thrombi.",
author = "C. Banfi and L. Mussoni and E. Tremoli",
year = "2002",
language = "Italian",
volume = "27",
pages = "181--191",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - PAI-1, il principale inibitore plasmatico della fibrinolisi. Ruolo fisiopatologico e meccanismi molecolari.

AU - Banfi, C.

AU - Mussoni, L.

AU - Tremoli, E.

PY - 2002

Y1 - 2002

N2 - Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in blood. PAI-1 is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular diseases. Plasma levels of PAI-1 are regulated on a genetic basis but, more important, is the dependence on a series of other atherosclerotic risk factors like hypertriglyceridemia, diabetes and insulin resistance. The insulin resistance syndrome, which is characterized partly by obesity with visceral fat accumulation, is considered as a major regulator of PAI-1 expression. At least in vitro, insulin is a potent inducer of PAI-1 synthesis by human hepatic cells, and, we have recently disentangled the molecular mechanisms responsible for enhanced PAI-1 gene expression by insulin. However, clinical data fail to support a direct acute contribution of insulin in regulating circulating PAI-1 levels. Recently, it has been proposed that adipose tissue could be responsible for the elevated plasma PAI-1 level observed in insulin resistance. It now seems reasonable to view PAI-1 as one of the factors contributing to the complex gene-environment interactions involved in the formation and dissolution of thrombi.

AB - Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in blood. PAI-1 is known to contribute to thrombus formation and to the development and the clinical course of acute and chronic cardiovascular diseases. Plasma levels of PAI-1 are regulated on a genetic basis but, more important, is the dependence on a series of other atherosclerotic risk factors like hypertriglyceridemia, diabetes and insulin resistance. The insulin resistance syndrome, which is characterized partly by obesity with visceral fat accumulation, is considered as a major regulator of PAI-1 expression. At least in vitro, insulin is a potent inducer of PAI-1 synthesis by human hepatic cells, and, we have recently disentangled the molecular mechanisms responsible for enhanced PAI-1 gene expression by insulin. However, clinical data fail to support a direct acute contribution of insulin in regulating circulating PAI-1 levels. Recently, it has been proposed that adipose tissue could be responsible for the elevated plasma PAI-1 level observed in insulin resistance. It now seems reasonable to view PAI-1 as one of the factors contributing to the complex gene-environment interactions involved in the formation and dissolution of thrombi.

UR - http://www.scopus.com/inward/record.url?scp=0036727604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036727604&partnerID=8YFLogxK

M3 - Articolo

C2 - 12091793

AN - SCOPUS:0036727604

VL - 27

SP - 181

EP - 191

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 3

ER -